Replacement treatment with biosynthetic human growth hormone in growth hormone-deficient hypopituitary adults.

Beshyah SA, Freemantle C, Shahi M, Anyaoku V, Merson S, Lynch S, Skinner E, Sharp P, Foale R, Johnston DG

Clinical endocrinology1 Jan 1995Cited by 75 (Europe PMC)

PMID7889635DOI10.1111/j.1365-2265.1995.tb02601.xPepBankPUB-07889635

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study23

23 results from studies that gave the peptide. 23 results from people.

01HumanRandomized controlled trialEfficacy outcome
In hypopituitary adults, lean body mass increased from 48.5 +/- 9.6 to 49.6 +/- 9.5 kg on GH, exceeding placebo (P < 0.05).
In plain wordsIn hypopituitary adults, GH increased lean body mass more than placebo.
Peptide
HGH (somatotropin)
Outcome
IncreaseControlled-phase lean body mass
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
0.04 (0.02-0.05) IU/kg daily · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Lean body mass
48.5 kg
GH group, start value (+/- 9.6), 6-month double blind phase
Lean body mass
49.6 kg
GH group, end value (+/- 9.5), 6-month double blind phase
Lean body mass
50.9 kg
Placebo group, start value (+/- 9.2), 6-month double blind phase
Lean body mass
50.1 kg
Placebo group, end value (+/- 9.0), 6-month double blind phase
Source sentences
Summary
Lean body mass (LBM) increased and percentage body fat (%BF) decreased on GH but not on placebo (P) (LBM: (GH: from 48.5 +/- 9.6 to 49.6 +/- 9.5 kg; P: from 50.9 +/- 9.2 to 50.1 +/- 9.0 kg, P < 0.05 GH vs P) and %BF (GH: from 34.7 +/- 11.4 to 34.2 +/- 10.7; P: from 37.4 +/- 7.6 to 38.7 +/- 8.1, P < 0.05 GH vs P)).
3 context sentences(design, population, supporting numbers)
Summary · context
A randomized double blind placebo controlled trial for 6 months followed by an open trial of GH treatment for 12 months.
Summary · context
GH daily dose was 0.04 (0.02-0.05) IU/kg s.c.
Summary · context
Forty GH deficient hypopituitary patients (19 M, 21 F; aged 19-67 years) on conventional replacement therapy were studied.
Report a problemFND-0788963502
02HumanRandomized controlled trialEfficacy outcome
In hypopituitary adults, percentage body fat decreased from 34.7 +/- 11.4 to 34.2 +/- 10.7 on GH, unlike placebo (P < 0.05).
In plain wordsIn hypopituitary adults, GH reduced percentage body fat compared with placebo.
Peptide
HGH (somatotropin)
Outcome
DecreaseControlled-phase percentage body fat
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
0.04 (0.02-0.05) IU/kg daily · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Percentage body fat
34.7%
GH group, start value (+/- 11.4), 6-month double blind phase
Percentage body fat
34.2%
GH group, end value (+/- 10.7), 6-month double blind phase
Percentage body fat
37.4%
Placebo group, start value (+/- 7.6), 6-month double blind phase
Percentage body fat
38.7%
Placebo group, end value (+/- 8.1), 6-month double blind phase
Source sentences
Summary
Lean body mass (LBM) increased and percentage body fat (%BF) decreased on GH but not on placebo (P) (LBM: (GH: from 48.5 +/- 9.6 to 49.6 +/- 9.5 kg; P: from 50.9 +/- 9.2 to 50.1 +/- 9.0 kg, P < 0.05 GH vs P) and %BF (GH: from 34.7 +/- 11.4 to 34.2 +/- 10.7; P: from 37.4 +/- 7.6 to 38.7 +/- 8.1, P < 0.05 GH vs P)).
3 context sentences(design, population, supporting numbers)
Summary · context
A randomized double blind placebo controlled trial for 6 months followed by an open trial of GH treatment for 12 months.
Summary · context
GH daily dose was 0.04 (0.02-0.05) IU/kg s.c.
Summary · context
Forty GH deficient hypopituitary patients (19 M, 21 F; aged 19-67 years) on conventional replacement therapy were studied.
Report a problemFND-0788963503
03HumanNon-randomized trialEfficacy outcome
In hypopituitary adults, waist circumference decreased significantly at 6 months of GH treatment.
In plain wordsIn hypopituitary adults, waist circumference decreased during GH treatment at 6 months.
Peptide
HGH (somatotropin)
Outcome
DecreaseWaist circumference
Study
n = 34
Outcome group
Body weight · Metabolic and weight
Studied dose
0.04 (0.02-0.05) IU/kg daily · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
Skinfold thicknesses decreased significantly at 6 and 12 months and the waist circumference at 6 months.
3 context sentences(design, population, supporting numbers)
Summary · context
A randomized double blind placebo controlled trial for 6 months followed by an open trial of GH treatment for 12 months.
Summary · context
GH daily dose was 0.04 (0.02-0.05) IU/kg s.c.
Summary · context
Forty GH deficient hypopituitary patients (19 M, 21 F; aged 19-67 years) on conventional replacement therapy were studied.
Report a problemFND-0788963509
04HumanNon-randomized trialEfficacy outcome
In hypopituitary adults, GH increased lean body mass from 49.6 +/- 9.1 to 51.6 +/- 9.4 kg at 6 months (P < 0.0006).
In plain wordsIn hypopituitary adults, lean body mass increased during GH treatment at 6 months.
Peptide
HGH (somatotropin)
Outcome
IncreaseLean body mass at 6 months
Study
n = 34
Outcome group
Body weight · Metabolic and weight
Studied dose
0.04 (0.02-0.05) IU/kg daily · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Lean body mass
49.6 kg
GH, start value (+/- 9.1)
Lean body mass
51.6 kg
GH, 6 months (+/- 9.4)
Source sentences
Summary
LBM increased on GH treatment from 49.6 +/- 9.1 to 51.6 +/- 9.4 kg (P < 0.0006), 51.9 +/- 8.9 kg (P < 0.07) and 53.1 +/- 10.5 kg (P < 0.0001) at 6, 12 and 18 months respectively.
4 context sentences(design, population, supporting numbers)
Summary · context
During longer-term follow-up combining the double blind and open phase components of the study, 34, 27 and 11 patients received GH for 6, 12 and 18 months respectively.
Summary · context
A randomized double blind placebo controlled trial for 6 months followed by an open trial of GH treatment for 12 months.
Summary · context
GH daily dose was 0.04 (0.02-0.05) IU/kg s.c.
Summary · context
Forty GH deficient hypopituitary patients (19 M, 21 F; aged 19-67 years) on conventional replacement therapy were studied.
Report a problemFND-0788963511
05HumanNon-randomized trialEfficacy outcome
In hypopituitary adults, GH reduced percentage body fat from 37.2 +/- 10.7 to 34.7 +/- 10.1 at 6 months (P < 0.005).
In plain wordsIn hypopituitary adults, percentage body fat decreased during GH treatment at 6 months.
Peptide
HGH (somatotropin)
Outcome
DecreasePercentage body fat at 6 months
Study
n = 34
Outcome group
Body weight · Metabolic and weight
Studied dose
0.04 (0.02-0.05) IU/kg daily · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Percentage body fat
37.2%
GH, start value (+/- 10.7)
Percentage body fat
34.7%
GH, 6 months (+/- 10.1)
Source sentences
Summary
Percentage body fat decreased on GH from 37.2 +/- 10.7 to 34.7 +/- 10.1 (P < 0.005), 35.1 +/- 12.8 (NS) and 34.5 +/- 8.6 (P < 0.04) at 6,12 and 18 months respectively.
4 context sentences(design, population, supporting numbers)
Summary · context
During longer-term follow-up combining the double blind and open phase components of the study, 34, 27 and 11 patients received GH for 6, 12 and 18 months respectively.
Summary · context
A randomized double blind placebo controlled trial for 6 months followed by an open trial of GH treatment for 12 months.
Summary · context
GH daily dose was 0.04 (0.02-0.05) IU/kg s.c.
Summary · context
Forty GH deficient hypopituitary patients (19 M, 21 F; aged 19-67 years) on conventional replacement therapy were studied.
Report a problemFND-0788963514
06HumanNon-randomized trialEfficacy outcome
In hypopituitary adults, waist-to-hip ratio decreased significantly on GH at 12 months.
In plain wordsIn hypopituitary adults, waist-to-hip ratio decreased during GH treatment at 12 months.
Peptide
HGH (somatotropin)
Outcome
DecreaseLonger-term waist-to-hip ratio
Study
n = 27
Outcome group
Body weight · Metabolic and weight
Studied dose
0.04 (0.02-0.05) IU/kg daily · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
Waist-to-hip ratio decreased significantly on GH at 12 months.
4 context sentences(design, population, supporting numbers)
Summary · context
During longer-term follow-up combining the double blind and open phase components of the study, 34, 27 and 11 patients received GH for 6, 12 and 18 months respectively.
Summary · context
A randomized double blind placebo controlled trial for 6 months followed by an open trial of GH treatment for 12 months.
Summary · context
GH daily dose was 0.04 (0.02-0.05) IU/kg s.c.
Summary · context
Forty GH deficient hypopituitary patients (19 M, 21 F; aged 19-67 years) on conventional replacement therapy were studied.
Report a problemFND-0788963510
07HumanNon-randomized trialEfficacy outcome
In hypopituitary adults, lean body mass rose from 49.6 +/- 9.1 to 51.9 +/- 8.9 kg at 12 months of GH (P < 0.07).
In plain wordsIn hypopituitary adults, lean body mass rose during GH treatment at 12 months, with P < 0.07.
Peptide
HGH (somatotropin)
Outcome
IncreaseLean body mass at 12 months
Study
n = 27
Outcome group
Body weight · Metabolic and weight
Studied dose
0.04 (0.02-0.05) IU/kg daily · subcutaneous · 12 monthsAs given in this study (human).
Measurements
Lean body mass
49.6 kg
GH, start value (+/- 9.1)
Lean body mass
51.9 kg
GH, 12 months (+/- 8.9)
Source sentences
Summary
LBM increased on GH treatment from 49.6 +/- 9.1 to 51.6 +/- 9.4 kg (P < 0.0006), 51.9 +/- 8.9 kg (P < 0.07) and 53.1 +/- 10.5 kg (P < 0.0001) at 6, 12 and 18 months respectively.
4 context sentences(design, population, supporting numbers)
Summary · context
During longer-term follow-up combining the double blind and open phase components of the study, 34, 27 and 11 patients received GH for 6, 12 and 18 months respectively.
Summary · context
A randomized double blind placebo controlled trial for 6 months followed by an open trial of GH treatment for 12 months.
Summary · context
GH daily dose was 0.04 (0.02-0.05) IU/kg s.c.
Summary · context
Forty GH deficient hypopituitary patients (19 M, 21 F; aged 19-67 years) on conventional replacement therapy were studied.
Report a problemFND-0788963512
08HumanNon-randomized trialEfficacy outcome
In hypopituitary adults, percentage body fat changed nonsignificantly from 37.2 +/- 10.7 to 35.1 +/- 12.8 at 12 months of GH.
In plain wordsIn hypopituitary adults, percentage body fat did not change significantly during GH treatment at 12 months.
Peptide
HGH (somatotropin)
Outcome
No significant changePercentage body fat at 12 months
Study
n = 27
Outcome group
Body weight · Metabolic and weight
Studied dose
0.04 (0.02-0.05) IU/kg daily · subcutaneous · 12 monthsAs given in this study (human).
Measurements
Percentage body fat, mean
37.2%
GH-treated, baseline
Percentage body fat, plus-minus spread (SD or SEM not stated)
10.7%
GH-treated, baseline
Percentage body fat, mean
35.1%
GH-treated, 12 months (NS)
Percentage body fat, plus-minus spread (SD or SEM not stated)
12.8%
GH-treated, 12 months
Source sentences
Summary
Percentage body fat decreased on GH from 37.2 +/- 10.7 to 34.7 +/- 10.1 (P < 0.005), 35.1 +/- 12.8 (NS) and 34.5 +/- 8.6 (P < 0.04) at 6,12 and 18 months respectively.
4 context sentences(design, population, supporting numbers)
Summary · context
During longer-term follow-up combining the double blind and open phase components of the study, 34, 27 and 11 patients received GH for 6, 12 and 18 months respectively.
Summary · context
A randomized double blind placebo controlled trial for 6 months followed by an open trial of GH treatment for 12 months.
Summary · context
GH daily dose was 0.04 (0.02-0.05) IU/kg s.c.
Summary · context
Forty GH deficient hypopituitary patients (19 M, 21 F; aged 19-67 years) on conventional replacement therapy were studied.
Report a problemFND-0788963515
09HumanNon-randomized trialEfficacy outcome
In hypopituitary adults, GH increased lean body mass from 49.6 +/- 9.1 to 53.1 +/- 10.5 kg at 18 months (P < 0.0001).
In plain wordsIn hypopituitary adults, lean body mass increased during GH treatment at 18 months.
Peptide
HGH (somatotropin)
Outcome
IncreaseLean body mass at 18 months
Study
n = 11
Outcome group
Body weight · Metabolic and weight
Studied dose
0.04 (0.02-0.05) IU/kg daily · subcutaneous · 18 monthsAs given in this study (human).
Measurements
Lean body mass
49.6 kg
GH, start value (+/- 9.1)
Lean body mass
53.1 kg
GH, 18 months (+/- 10.5)
Source sentences
Summary
LBM increased on GH treatment from 49.6 +/- 9.1 to 51.6 +/- 9.4 kg (P < 0.0006), 51.9 +/- 8.9 kg (P < 0.07) and 53.1 +/- 10.5 kg (P < 0.0001) at 6, 12 and 18 months respectively.
4 context sentences(design, population, supporting numbers)
Summary · context
During longer-term follow-up combining the double blind and open phase components of the study, 34, 27 and 11 patients received GH for 6, 12 and 18 months respectively.
Summary · context
A randomized double blind placebo controlled trial for 6 months followed by an open trial of GH treatment for 12 months.
Summary · context
GH daily dose was 0.04 (0.02-0.05) IU/kg s.c.
Summary · context
Forty GH deficient hypopituitary patients (19 M, 21 F; aged 19-67 years) on conventional replacement therapy were studied.
Report a problemFND-0788963513
10HumanNon-randomized trialEfficacy outcome
In hypopituitary adults, GH reduced percentage body fat from 37.2 +/- 10.7 to 34.5 +/- 8.6 at 18 months (P < 0.04).
In plain wordsIn hypopituitary adults, percentage body fat decreased during GH treatment at 18 months.
Peptide
HGH (somatotropin)
Outcome
DecreasePercentage body fat at 18 months
Study
n = 11
Outcome group
Body weight · Metabolic and weight
Studied dose
0.04 (0.02-0.05) IU/kg daily · subcutaneous · 18 monthsAs given in this study (human).
Measurements
Percentage body fat, mean
37.2%
GH-treated, baseline
Percentage body fat, plus-minus spread (SD or SEM not stated)
10.7%
GH-treated, baseline
Percentage body fat, mean
34.5%
GH-treated, 18 months (P < 0.04)
Percentage body fat, plus-minus spread (SD or SEM not stated)
8.6%
GH-treated, 18 months
Source sentences
Summary
Percentage body fat decreased on GH from 37.2 +/- 10.7 to 34.7 +/- 10.1 (P < 0.005), 35.1 +/- 12.8 (NS) and 34.5 +/- 8.6 (P < 0.04) at 6,12 and 18 months respectively.
4 context sentences(design, population, supporting numbers)
Summary · context
During longer-term follow-up combining the double blind and open phase components of the study, 34, 27 and 11 patients received GH for 6, 12 and 18 months respectively.
Summary · context
A randomized double blind placebo controlled trial for 6 months followed by an open trial of GH treatment for 12 months.
Summary · context
GH daily dose was 0.04 (0.02-0.05) IU/kg s.c.
Summary · context
Forty GH deficient hypopituitary patients (19 M, 21 F; aged 19-67 years) on conventional replacement therapy were studied.
Report a problemFND-0788963516
11HumanNon-randomized trialSafety outcome
In hypopituitary adults, two GH-treated patients withdrew because of adverse events during the 6-month double blind phase.
In plain wordsIn hypopituitary adults, two GH-treated patients withdrew because of adverse events during the controlled phase.
Peptide
HGH (somatotropin)
Outcome
Not applicableAdverse-event withdrawals
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
0.04 (0.02-0.05) IU/kg daily · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Withdrawals due to adverse events
2 patients
GH treated patients, 6-month double blind phase
Source sentences
Summary
During the 6-month double blind phase, two GH treated patients withdrew because of adverse events.
3 context sentences(design, population, supporting numbers)
Summary · context
A randomized double blind placebo controlled trial for 6 months followed by an open trial of GH treatment for 12 months.
Summary · context
GH daily dose was 0.04 (0.02-0.05) IU/kg s.c.
Summary · context
Forty GH deficient hypopituitary patients (19 M, 21 F; aged 19-67 years) on conventional replacement therapy were studied.
Report a problemFND-0788963501
12HumanNon-randomized trialEfficacy outcome
In hypopituitary adults, total body water increased on GH (P < 0.01) but not placebo.
In plain wordsIn hypopituitary adults, total body water increased on GH but not placebo.
Peptide
HGH (somatotropin)
Outcome
IncreaseControlled-phase total body water
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
0.04 (0.02-0.05) IU/kg daily · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
TBW increased on GH (P < 0.01) but not on P.
3 context sentences(design, population, supporting numbers)
Summary · context
A randomized double blind placebo controlled trial for 6 months followed by an open trial of GH treatment for 12 months.
Summary · context
GH daily dose was 0.04 (0.02-0.05) IU/kg s.c.
Summary · context
Forty GH deficient hypopituitary patients (19 M, 21 F; aged 19-67 years) on conventional replacement therapy were studied.
Report a problemFND-0788963504
13HumanNon-randomized trialEfficacy outcome
In hypopituitary adults, waist-to-hip ratio did not change during the controlled GH phase.
In plain wordsIn hypopituitary adults, waist-to-hip ratio did not change during the controlled GH phase.
Peptide
HGH (somatotropin)
Outcome
No significant changeControlled-phase waist-to-hip ratio
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
0.04 (0.02-0.05) IU/kg daily · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
No change was observed in waist-to-hip ratio or in muscle strength.
3 context sentences(design, population, supporting numbers)
Summary · context
A randomized double blind placebo controlled trial for 6 months followed by an open trial of GH treatment for 12 months.
Summary · context
GH daily dose was 0.04 (0.02-0.05) IU/kg s.c.
Summary · context
Forty GH deficient hypopituitary patients (19 M, 21 F; aged 19-67 years) on conventional replacement therapy were studied.
Report a problemFND-0788963505
14HumanNon-randomized trialEfficacy outcome
In hypopituitary adults, muscle strength did not change during the controlled GH phase.
In plain wordsIn hypopituitary adults, muscle strength did not change during the controlled GH phase.
Peptide
HGH (somatotropin)
Outcome
No significant changeControlled-phase muscle strength
Study
n: not reported in source
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
0.04 (0.02-0.05) IU/kg daily · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
No change was observed in waist-to-hip ratio or in muscle strength.
3 context sentences(design, population, supporting numbers)
Summary · context
A randomized double blind placebo controlled trial for 6 months followed by an open trial of GH treatment for 12 months.
Summary · context
GH daily dose was 0.04 (0.02-0.05) IU/kg s.c.
Summary · context
Forty GH deficient hypopituitary patients (19 M, 21 F; aged 19-67 years) on conventional replacement therapy were studied.
Report a problemFND-0788963506
15HumanNon-randomized trialSafety outcome
In hypopituitary adults, patients discontinued longer-term GH treatment because of adverse events or lack of perceived benefit.
In plain wordsIn hypopituitary adults, patients stopped longer-term GH treatment because of adverse events or lack of perceived benefit.
Peptide
HGH (somatotropin)
Outcome
Not applicableLonger-term discontinuations
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
0.04 (0.02-0.05) IU/kg daily · subcutaneousAs given in this study (human).
Source sentences
Summary
Patients dropped out because of adverse events or lack of perceived benefit.
3 context sentences(design, population, supporting numbers)
Summary · context
A randomized double blind placebo controlled trial for 6 months followed by an open trial of GH treatment for 12 months.
Summary · context
GH daily dose was 0.04 (0.02-0.05) IU/kg s.c.
Summary · context
Forty GH deficient hypopituitary patients (19 M, 21 F; aged 19-67 years) on conventional replacement therapy were studied.
Report a problemFND-0788963507
16HumanNon-randomized trialEfficacy outcome
In hypopituitary adults, skinfold thickness decreased significantly at 6 and 12 months of GH treatment.
In plain wordsIn hypopituitary adults, skinfold thickness decreased during GH treatment at 6 and 12 months.
Peptide
HGH (somatotropin)
Outcome
DecreaseSkinfold thickness
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
0.04 (0.02-0.05) IU/kg daily · subcutaneous · 6 and 12 monthsAs given in this study (human).
Source sentences
Summary
Skinfold thicknesses decreased significantly at 6 and 12 months and the waist circumference at 6 months.
3 context sentences(design, population, supporting numbers)
Summary · context
A randomized double blind placebo controlled trial for 6 months followed by an open trial of GH treatment for 12 months.
Summary · context
GH daily dose was 0.04 (0.02-0.05) IU/kg s.c.
Summary · context
Forty GH deficient hypopituitary patients (19 M, 21 F; aged 19-67 years) on conventional replacement therapy were studied.
Report a problemFND-0788963508
17HumanNon-randomized trialEfficacy outcome
In hypopituitary adults, total body water increased at 6 and 12 months of GH treatment.
In plain wordsIn hypopituitary adults, total body water increased during GH treatment at 6 and 12 months.
Peptide
HGH (somatotropin)
Outcome
IncreaseLonger-term total body water
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
0.04 (0.02-0.05) IU/kg daily · subcutaneous · 6 and 12 monthsAs given in this study (human).
Source sentences
Summary
TBW also increased at 6 and 12 months of GH treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
A randomized double blind placebo controlled trial for 6 months followed by an open trial of GH treatment for 12 months.
Summary · context
GH daily dose was 0.04 (0.02-0.05) IU/kg s.c.
Summary · context
Forty GH deficient hypopituitary patients (19 M, 21 F; aged 19-67 years) on conventional replacement therapy were studied.
Report a problemFND-0788963517
18HumanNon-randomized trialEfficacy outcome
In hypopituitary adults, exercise time increased significantly at 6, 12 and 18 months of GH treatment.
In plain wordsIn hypopituitary adults, exercise time increased during GH treatment at 6, 12 and 18 months.
Peptide
HGH (somatotropin)
Outcome
IncreaseExercise time
Study
n: not reported in source
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
0.04 (0.02-0.05) IU/kg daily · subcutaneous · 6, 12 and 18 monthsAs given in this study (human).
Source sentences
Summary
Exercise time increased significantly at 6, 12 and 18 months of GH treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
A randomized double blind placebo controlled trial for 6 months followed by an open trial of GH treatment for 12 months.
Summary · context
GH daily dose was 0.04 (0.02-0.05) IU/kg s.c.
Summary · context
Forty GH deficient hypopituitary patients (19 M, 21 F; aged 19-67 years) on conventional replacement therapy were studied.
Report a problemFND-0788963518
19HumanNon-randomized trialEfficacy outcome
In hypopituitary adults, strength in selected muscle groups increased significantly at 6, 12 or 18 months of GH treatment.
In plain wordsIn hypopituitary adults, selected muscle groups became stronger during GH treatment at 6, 12 or 18 months.
Peptide
HGH (somatotropin)
Outcome
IncreaseSelected muscle-group strength
Study
n: not reported in source
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
0.04 (0.02-0.05) IU/kg daily · subcutaneous · 6, 12 or 18 monthsAs given in this study (human).
Source sentences
Summary
Muscle strength in selected muscle groups increased significantly at 6, 12 or 18 months of GH treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
A randomized double blind placebo controlled trial for 6 months followed by an open trial of GH treatment for 12 months.
Summary · context
GH daily dose was 0.04 (0.02-0.05) IU/kg s.c.
Summary · context
Forty GH deficient hypopituitary patients (19 M, 21 F; aged 19-67 years) on conventional replacement therapy were studied.
Report a problemFND-0788963519
20HumanNon-randomized trialEfficacy outcome
In hypopituitary adults in the 6-month controlled phase, GHQ scores improved on placebo but not on GH, and the placebo group had higher GHQ scores (higher morbidity) before therapy.
In plain wordsIn hypopituitary adults, GHQ scores improved on placebo but not on GH, and the placebo group started with worse scores.
Peptide
HGH (somatotropin)
Outcome
No significant changeControlled-phase GHQ score
Study
n: not reported in source
Comparator
Placebo
Outcome group
Quality of life · Mental health and mood
Studied dose
0.04 (0.02-0.05) IU/kg daily · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
Over the controlled phase, GHQ scores improved on placebo but not on GH and CPRS score was unchanged in either group.
4 context sentences(design, population, supporting numbers)
Summary · context
A randomized double blind placebo controlled trial for 6 months followed by an open trial of GH treatment for 12 months.
Summary · context
GH daily dose was 0.04 (0.02-0.05) IU/kg s.c.
Summary · context
Forty GH deficient hypopituitary patients (19 M, 21 F; aged 19-67 years) on conventional replacement therapy were studied.
Summary · context
Randomization resulted in the placebo group having a greater GHQ score (higher morbidity) than the GH group before therapy.
Report a problemFND-0788963520
21HumanNon-randomized trialEfficacy outcome
In hypopituitary adults, CPRS scores remained unchanged during both GH and placebo treatment.
In plain wordsIn hypopituitary adults, CPRS scores did not change during GH or placebo treatment.
Peptide
HGH (somatotropin)
Outcome
No significant changeControlled-phase CPRS score
Study
n: not reported in source
Comparator
Placebo
Outcome group
Quality of life · Mental health and mood
Studied dose
0.04 (0.02-0.05) IU/kg daily · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
Over the controlled phase, GHQ scores improved on placebo but not on GH and CPRS score was unchanged in either group.
3 context sentences(design, population, supporting numbers)
Summary · context
A randomized double blind placebo controlled trial for 6 months followed by an open trial of GH treatment for 12 months.
Summary · context
GH daily dose was 0.04 (0.02-0.05) IU/kg s.c.
Summary · context
Forty GH deficient hypopituitary patients (19 M, 21 F; aged 19-67 years) on conventional replacement therapy were studied.
Report a problemFND-0788963521
22HumanNon-randomized trialEfficacy outcome
In hypopituitary adults, GHQ scores did not change during open-phase GH therapy.
In plain wordsIn hypopituitary adults, GHQ scores did not change during open-phase GH therapy.
Peptide
HGH (somatotropin)
Outcome
No significant changeOpen-phase GHQ score
Study
n: not reported in source
Outcome group
Quality of life · Mental health and mood
Studied dose
0.04 (0.02-0.05) IU/kg daily · subcutaneousAs given in this study (human).
Source sentences
Summary
In the open phase, the GHQ score did not change on GH therapy but CPRS score improved at 6 and 12 months.
3 context sentences(design, population, supporting numbers)
Summary · context
A randomized double blind placebo controlled trial for 6 months followed by an open trial of GH treatment for 12 months.
Summary · context
GH daily dose was 0.04 (0.02-0.05) IU/kg s.c.
Summary · context
Forty GH deficient hypopituitary patients (19 M, 21 F; aged 19-67 years) on conventional replacement therapy were studied.
Report a problemFND-0788963522
23HumanNon-randomized trialEfficacy outcome
In hypopituitary adults, CPRS scores improved during open-phase GH therapy at 6 and 12 months.
In plain wordsIn hypopituitary adults, CPRS scores improved during open-phase GH therapy at 6 and 12 months.
Peptide
HGH (somatotropin)
Outcome
Direction not reportedOpen-phase CPRS score
Study
n: not reported in source
Outcome group
Quality of life · Mental health and mood
Studied dose
0.04 (0.02-0.05) IU/kg daily · subcutaneous · 6 and 12 monthsAs given in this study (human).
Source sentences
Summary
In the open phase, the GHQ score did not change on GH therapy but CPRS score improved at 6 and 12 months.
3 context sentences(design, population, supporting numbers)
Summary · context
A randomized double blind placebo controlled trial for 6 months followed by an open trial of GH treatment for 12 months.
Summary · context
GH daily dose was 0.04 (0.02-0.05) IU/kg s.c.
Summary · context
Forty GH deficient hypopituitary patients (19 M, 21 F; aged 19-67 years) on conventional replacement therapy were studied.
Report a problemFND-0788963523

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.